Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 11;86(2):e72-e76.
doi: 10.1055/a-2558-6468. eCollection 2025 Apr.

Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report

Russel T Wagner  1 , Jacopo Berardinelli  2 , Melanie B Fukui  1 , Sammy Khalili  1 , Neil S Mundi  1 , Amin B Kassam  1 , Stephen J Winkler  1
Affiliations
Case Reports

Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report

Russel T Wagner et al. J Neurol Surg Rep. .

Abstract

This case report presents a 29-year-old male with diabetes mellitus who developed rhino-orbito-cerebral mucormycosis (ROCM) that was successfully treated with liposomal amphotericin B orbital injections. Despite emergent endoscopic debridement, the patient's disease progressed intracranially and intraorbitally, but he declined further surgical intervention. Subsequently, due to rapid acute vision loss, we initiated transcutaneous retrobulbar amphotericin B (TRAMB) injections. Following these injections, visual acuity, motility, and intraorbital fungal burden improved despite intracranial progression. This report highlights the benefits of TRAMB administration in aggressive fungal infections and explores the mechanisms behind its effectiveness, particularly in globe preservation. By targeting the infection in an area with a relatively robust blood supply, TRAMB reduces surgical difficulty and improves overall outcomes.

Keywords: TRAMB injections; amphotericin B; antifungal therapy; diabetes mellitus; fungal infection; globe preservation; intracranial extension; minimally invasive treatment; orbital mucormycosis; preoperative management.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Preoperative coronal CT showing the sinonasal involvement of the infection.
Fig. 2
Fig. 2
Table of the treatment course of 1 mL of 3.5 mg liposomal amphotericin B injections performed in the supramedial orbit. The table documents clinical improvements of vision from the injections. Abbreviations: APD, afferent pupillary defect; EOM, extraocular motility.
Fig. 3
Fig. 3
( A, B ) Axial MRIs taken before and after the liposomal amphotericin B injections, showing the orbital improvements. ( C, D ) Coronal MRIs taken before and after the liposomal amphotericin B injections further highlight the orbital improvement. ( E, F ) Axial MRIs taken before and after the liposomal amphotericin B injections, showing the intracranial progression.
Fig. 4
Fig. 4
( A ) Postoperative axial MRI showing the intracranial cuts where the fungus was resected. B ) Postoperative axial MRI showing decompressed optic nerve and drastic decrease in proptosis. ( C ) Postoperative coronal MRI showing decompressed optic nerve.
See this image and copyright information in PMC

References

    1. Chakrabarti A, Das A, Mandal J et al.The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(04):335–342. - PubMed
    1. Sharifi A, Akbari Z, Shafie'ei M et al.Retrobulbar injection of amphotericin B in patients with COVID-19 associated orbital mucormycosis: A systematic review. Ophthalmic Plast Reconstr Surg. 2022;38(05):425–432. - PMC - PubMed
    1. Biradar S, Patil S N, Kadeli D. Mucormycosis in a diabetic ketoacidosis patient: A case report. J Clin Diagn Res. 2016;10(05):OD09–OD10. - PMC - PubMed
    1. Bhandari J, Thada P K, Nagalli S.Rhinocerebral Mucormycosis. (Updated September 15, 2023)In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Accessed March 25, 2025 at:https://www.ncbi.nlm.nih.gov/books/NBK559288/ - PubMed
    1. Binder U, Maurer E, Lass-Flörl C. Mucormycosis–from the pathogens to the disease. Clin Microbiol Infect. 2014;20 06:60–66. - PubMed

Publication types